452 related articles for article (PubMed ID: 16240851)
1. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
Breedveld FC
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
[TBL] [Abstract][Full Text] [Related]
2. Differentiating the efficacy of tumor necrosis factor inhibitors.
Haraoui B
J Rheumatol Suppl; 2005 Mar; 74():3-7. PubMed ID: 15742457
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
Baker DE
Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
[TBL] [Abstract][Full Text] [Related]
5. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
6. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
7. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
8. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease.
Kooloos WM; de Jong DJ; Huizinga TW; Guchelaar HJ
Drug Discov Today; 2007 Feb; 12(3-4):125-31. PubMed ID: 17275732
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor inhibitors.
Nash PT; Florin TH
Med J Aust; 2005 Aug; 183(4):205-8. PubMed ID: 16097922
[TBL] [Abstract][Full Text] [Related]
10. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
12. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
Davies A; Cifaldi MA; Segurado OG; Weisman MH
J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
[TBL] [Abstract][Full Text] [Related]
14. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
Lanfant-Weybel K; Lequerré T; Vittecoq O
Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
[TBL] [Abstract][Full Text] [Related]
15. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
[TBL] [Abstract][Full Text] [Related]
16. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
[TBL] [Abstract][Full Text] [Related]
17. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
Karampetsou MP; Liossis SN; Sfikakis PP
QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
19. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
[TBL] [Abstract][Full Text] [Related]
20. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
